Table 3.
Logistic regression analysis of systemic inflammation markers, pre‐treatment sarcopenia, and skeletal muscle index loss
| Odds ratio (95% CI) | P‐value | |
|---|---|---|
| Pre‐treatment sarcopeniaa | ||
| mGPS | ||
| mGPS 0 | Reference | |
| mGPS 1–2 | 2.37 (1.01–5.54) | 0.04 |
| NLR | ||
| NLR ≤3 | Reference | |
| NLR >3 | 0.81 (0.35–1.88) | 0.63 |
| PLR | ||
| PLR ≤150 | Reference | |
| PLR >150 | 1.60 (0.59–4.37) | 0.36 |
| SMI loss ≥5%b | ||
| mGPS | ||
| mGPS 0 | Reference | |
| mGPS 1–2 | 2.42 (1.03–5.69) | 0.04 |
| NLR | ||
| NLR ≤3 | Reference | |
| NLR >3 | 1.66 (0.76–3.64) | 0.21 |
| PLR | ||
| PLR ≤150 | Reference | |
| PLR >150 | 1.57 (0.62–3.99) | 0.35 |
Bolded P‐values are those significant with a P < 0.05. CI, confidence interval; mGPS, modified Glasgow prognostic score; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SMI, skeletal muscle index.
a
Model adjusted for age and body mass index.
b
Model adjusted for age, body mass index, residual disease after primary debulking surgery, and malignant ascites.